The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-analysis
Abstract
IMPORTANCE: Staphylococcus aureus bacteremia (SAB) is a worldwide problem. It is unclear whether higher-vancomycin minimum inhibitory concentration (MIC) is associated with mortality. This potential association has direct consequences for patients and public health. DATA SOURCES: PubMed, Embase, the Cochrane Library, Evidence-based Medicine BMJ, and the American College of Physicians Journal Club were searched from inception through April 2014. STUDY SELECTION: Studies reporting mortality and vancomycin MIC in patients with SAB were included. DATA EXTRACTION AND SYNTHESIS: Two authors performed the literature search and the study selection separately. Random-effects modeling was used for all analyses. MAIN OUTCOMES AND MEASURES: All-cause mortality. FINDINGS: Among 38 included studies that involved 8291 episodes of SAB, overall mortality was 26.1%. The estimated mortality was 26.8% among SAB episodes (n = 2740) in patients with high-vancomycin MIC (≥1.5 mg/L) compared with 25.8% mortality among SAB episodes (n = 5551) in patients with low-vancomycin MIC (<1.5 mg/L) (adjusted risk difference [RD], 1.6% [95% CI, -2.3% to 5.6%]; P = .43). For the highest-quality studies, the estimated mortality was 26.2% among SAB episodes (n = 2318) in patients with high-vancomycin MIC compared with 27.8% mortality among SAB episodes (n = 4168) in patients with low-vancomycin MIC (RD, 0.9% [95% CI, -2.9% to 4.6%]; P = .65). In studies that included only methicillin-resistant S aureus infections (n = 7232), the mortality among SAB episodes (n = 2384) in patients with high-vancomycin MIC was 27.6% compared with mortality of 27.4% among SAB episodes (n = 4848) in patients with low-vancomycin MIC (adjusted RD, 1.6% [95% CI, -2.3% to 5.5%]; P = .41). No significant differences in risk of death were observed in subgroups with high-vancomycin MIC vs low-vancomycin MIC values across different study designs, microbiological susceptibility assays, MIC cutoffs, clinical outcomes, duration of bacteremia, previous vancomycin exposure, and treatment with vancomycin. CONCLUSIONS AND RELEVANCE: In this meta-analysis of SAB episodes, there were no statistically significant differences in the risk of death when comparing patients with S aureus exhibiting high-vancomycin MIC (≥1.5 mg/L) to those with low-vancomycin MIC (<1.5 mg/L), although the findings cannot definitely exclude an increased mortality risk. These findings should be considered when interpreting vancomycin susceptibility and in determining whether alternative antistaphylococcal agents are necessary for patients with SAB with elevated but susceptible vancomycin MIC values.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Roberts, J. A., Taccone, F. S., Udy, A. A., Vincent, J.-L., Jacobs, F., & Lipman, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01708-10 · Cited by 226
Bae, I., Federspiel, J. J., Miró, J. M., Woods, C. W., Park, L., Rybak, M. J., Rude, T. H., Bradley, S., Bukovski, S., de la Maria, C. G., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606027 · Cited by 122
Jang, H., Kim, S., Kim, K. H., Kim, C. J., Lee, S., Song, K., Jeon, J. H., Park, W. B., Kim, H. B., Park, S., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/600295 · Cited by 113
Gasch, O., Camoez, M., Dominguez, M. A., Padilla, B., Pintado, V., Almirante, B., Molina, J., Lopez-Medrano, F., Ruiz, E., Martinez, J. A., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12108 · Cited by 86
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Self-citationHassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
The Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Clinical Impact of Staphylococcus aureus Skin and Soft Tissue Infections
Linz, M. S., Mattappallil, A., Finkel, D., & Parker, D. (2023) · Antibiotics · doi:10.3390/antibiotics12030557 · Cited by 293
Metadata
- Authors
- Kalil, A. C., Van Schooneveld, T. C., Fey, P. D., & Rupp, M. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-10-15
- Volume
- 312
- Issue
- 15
- Pages
- 1552
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2104839672
- Cited by
- 172
- References
- 5
- FWCI
- 19.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1001/jama.2014.6364
- The paper
- Kalil, A. C., Van Schooneveld, T. C., Fey, P. D., & Rupp, M. E. (2014). Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-analysis. JAMA. https://doi.org/10.1001/jama.2014.6364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.